ARCHIVES

A Year in Houston: DePinho Reflects on Plans, Conflicts, Controversies—and Lessons Learned

This article is from The Cancer Letter archive.

Vol. 38 No. 33 | September 7, 2012

Download PDF Visit The Full Archive

Related Articles

CTI Files Appeal Over FDA’s Decision on Pixantrone

December 3, 2010

NCI-Approved Clinical Trials

October 29, 2004

DeVita Losing Patience, Responds To Powers Letter

May 6, 1983

Stop Cancer Foundation’s Future In Question, May Not Deliver All Of Funds Promised to NCI

January 18, 1991

NCI Director Andrew von Eschenbach To Resign June 10, Remain As FDA Acting Commissioner.

June 2, 2006

Toxicology Program Board To Review Nine Substances.

January 14, 2000